Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) was the target of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 2,170,107 shares, a drop of 0.0% from the October 14th total of 2,170,966 shares. Approximately 4.3% of the company’s shares are sold short. Based on an average trading volume of 470,747 shares, the days-to-cover ratio is presently 4.6 days.

Actinium Pharmaceuticals (NYSEMKT:ATNM) opened at 1.0199 on Thursday. Actinium Pharmaceuticals has a 1-year low of $0.86 and a 1-year high of $3.50. The stock’s 50 day moving average is $1.07 and its 200-day moving average is $1.57. The company’s market capitalization is $56.86 million.

Several institutional investors have recently made changes to their positions in ATNM. Sio Capital Management LLC acquired a new position in Actinium Pharmaceuticals during the third quarter valued at $2,160,000. Vanguard Group Inc. increased its position in Actinium Pharmaceuticals by 19.2% in the second quarter. Vanguard Group Inc. now owns 1,581,228 shares of the company’s stock valued at $2,798,000 after buying an additional 254,318 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Actinium Pharmaceuticals by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 462,683 shares of the company’s stock valued at $819,000 after buying an additional 47,131 shares during the period. GSA Capital Partners LLP acquired a new position in Actinium Pharmaceuticals during the second quarter valued at $247,000. Finally, D.A. Davidson & CO. increased its position in Actinium Pharmaceuticals by 41.1% in the third quarter. D.A. Davidson & CO. now owns 127,000 shares of the company’s stock valued at $171,000 after buying an additional 37,000 shares during the period.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/24/actinium-pharmaceuticals-inc-atnm-short-interest-down-0-0-in-october.html.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Stock Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.